Lunai Bioworks Inc. (LNAI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lunai Bioworks Inc. on December 2, 2025. The filing discloses the entry into a material definitive agreement to facilitate an equity offering. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol LNAI.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. The primary financial data point disclosed is the potential capital raise:
- Maximum Offering Size: Up to $11.70 million in aggregate offering price.
- Compensation to Sales Agent: 3.0% of gross proceeds from sales.
- Registration Basis: Sales will be made under an effective Form S-3 (File No. 333-282898) declared effective on November 6, 2024.
Material Changes
The material change reported is the execution of an At-the-Market Sales Agreement with Dawson James Securities, Inc. on December 2, 2025. This agreement authorizes the Company to sell shares of its common stock from time to time through the Sales Agent as its sales agent. The Company is not obligated to sell any shares and may suspend sales at any time.
Guidance, Outlook, and Risks
The filing includes forward-looking statements regarding the Company's strategy and future operations, including:
- Expected revenue growth potential of subsidiaries.
- Timeline for commercializing the BE-Smart Esophageal Cancer Test.
- Expectations regarding future liquidity events.
- Efforts to collect accounts receivables.
- Transition into a consumer products company.
Risks and Contingencies: Management cautions that actual results may differ materially due to risks including the ability to obtain regulatory approvals, general economic conditions, consumer demand, challenges in growing new business lines, and competitive environment. The Company undertakes no obligation to update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the current market price of LNAI to assess potential dilution from the $11.70 million offering.
- Review the full text of the At-the-Market Sales Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Check recent 10-K or 10-Q filings for current cash balances and burn rate to understand the necessity of this capital raise.
- Monitor regulatory status updates regarding the BE-Smart Esophageal Cancer Test.
- Confirm the status of accounts receivable collections mentioned in the forward-looking statements.